Risk Factors of Acute Radiation-Induced Lung Injury Induced by Radiotherapy for Esophageal Cancer

Faen Zhang, Lihua Liao, Song Wei, and Yuqing Lu

Department of Oncology, The People’s Hospital of Hechi, Guangxi 547000, China

Correspondence should be addressed to Faen Zhang; zhanfae@163.com

Received 24 May 2022; Revised 28 June 2022; Accepted 4 July 2022; Published 13 July 2022

Objective. To investigate the risk factors of acute radiation-induced lung injury (acute RILI) induced by radiotherapy for esophageal cancer.

Methods. A total of 206 patients with esophageal cancer who received radiotherapy in our hospital from January 2017 to March 2020 were selected. The general data such as gender, age, and comorbidities of the patients were collected, as well as the levels of cytokines (TNF-α, TNF-β, and IL-6) in peripheral blood before radiotherapy; radiotherapy dose-related parameters were recorded during radiotherapy. Follow-up was 12 months after radiotherapy. The patients with induced acute RILI after radiotherapy were set as the observation group (n = 75). Patients without acute RILI after radiotherapy were set as the control group (n = 131). Univariate and multivariate logistic regression analysis was performed on the risk factors of acute RILI induced by radiotherapy for esophageal cancer.

Results. Univariate analysis and multivariate logistic regression analysis showed that the combined diabetes, total radiation dose, combined lung disease, physical factors (V30, Dmean), and preradiotherapy cytokine (TNF-α, TNF-β, and IL-6) elevated level was an independent risk factor for radiotherapy-induced acute RILI in esophageal cancer (P < 0.05). Conclusion. Concomitant diabetes, total radiation dose, lung disease, physical factors (V30, Dmean), and levels of cytokines (TNF-α, TNF-β, and IL-6) before radiation therapy are risk factors for acute RILI induced by radiation therapy in esophageal cancer. The possibility of acute RILI should be comprehensively assessed according to the patient’s condition, and the radiotherapy regimen should be adjusted to reduce and avoid the induction of acute radiation-induced lung injury.

1. Introduction

Esophageal cancer is a malignant tumor that occurs in the esophageal epithelium. Its typical manifestation is progressive aggravating dysphagia, which is one of the main malignant tumors that threaten the health of residents [1]. The incidence and mortality of esophageal cancer vary widely in different countries, and China is a country with a high incidence of esophageal cancer and one of the countries with a high mortality rate of esophageal cancer in the world [2]. There are gender, age, and regional differences in the incidence of esophageal cancer. The prevalence and mortality of esophageal cancer in men are higher than those in women, and the peak age of incidence is 45-80 years old. The incidence of esophageal cancer in rural areas is higher than that in urban areas [3]. The preferred method of treatment for early-stage esophageal cancer is surgery. Once a patient with esophageal cancer is diagnosed, surgical treatment should be performed when physical conditions permit. Combined radiotherapy and surgery can increase surgical resection rate and improve long-term survival rate [4]. However, radiation therapy easily damages the normal lung tissue within the radiation field, which in turn causes an inflammatory response in the body, resulting in acute radiation lung injury (acute RILI) [5]. Acute RILI not only affects the efficacy of radiotherapy but also reduces the quality of life of patients and even leads to death of patients. At present, the risk factors of acute RILI induced by radiotherapy for esophageal cancer have not been fully clarified, and there may be regional differences. Therefore, this study explored
the risk factors of acute RILI induced by radiotherapy for esophageal cancer in Hechi City, Guangxi, and was aimed at finding an effective preventive method for acute RILI.

2. Materials and Methods

2.1. General Information. A total of 206 patients with esophageal cancer who received radiotherapy at the People’s Hospital of Hechi from January 2017 to March 2020 were selected. Inclusion criteria were as follows: (1) patients with complete medical records and meeting the diagnostic criteria for esophageal cancer [6]; (2) patients who completed the first radiotherapy and subsequent radiotherapy in the People’s Hospital of Hechi; (3) Karnofsky performance score (KPS) ≥ 70 points and no vocal cord paralysis; and (4) computed tomography (CT) examination showed that the tumor did not invade the aorta or tracheobronchial and other adjacent tissues and organs, and there was no obvious external invasion. Exclusion criteria were as follows: (1) patients with contraindications to radiotherapy; (2) patients with major dysfunction of the heart, liver, kidney, lung, and other organs; (3) patients with distant metastasis or esophageal fistula; and (4) patients with mental disorders and uncooperative patients.

2.2. Research Methods. All patients were treated with a Varian Clinac CX type 4994 linear accelerator. The radiotherapy was completed by the professional radiation therapist giving instructions of the kit (Shanghai Enzyme Link Biotechnology Co., Ltd.) and the instrument to perform the testing operation: TNF-α kit item number: ml-E12414, TNF-β kit item number: ml-063192, and IL-6 kit item number: ml-E12436.

The patients were followed up for 3 months after radiotherapy. The patients with acute RILI induced by radiotherapy were set as the observation group, and the patients without acute RILI after radiotherapy were set as the control group.

2.3. Observation Indicators. Clinical data: age, gender, tumor location, tumor stage, smoking history, diabetes, lung disease, concurrent chemotherapy, and KPS score.

Physical parameters: the percentage of lung volume in the total lung volume when both lungs were irradiated with 5 Gy, 10 Gy, 20 Gy, 30 Gy, and 40 Gy (V5, V10, V20, V30, V40), the average dose of bilateral lung irradiation (Dmean), and total radiation dose.

Cytokines: TNF-α, TNF-β, and IL-6 levels in peripheral blood serum before radiotherapy.

KPS scoring standard: according to the patient’s health status score, 10 points are a grade, and the highest score was 100 points. A score of ≥80 was classified as a nondependent level; that is, patients can take care of themselves; 50-70 was classified as a semidependent level; that is, patient requires partial care; a score below 50 was a dependent level; that is, patient is in complete need of care.

Acute RILI evaluation criteria: evaluation of acute RILI according to Common Terminology Criteria for Adverse Events 4.0 (CTCAE v4.0). Lung injury within 3 months from the first day of radiotherapy was defined as acute RILI, so all patients were followed up for 3 months after IMRT. Repeat chest CT at follow-up. According to the American Radiation Therapy Oncology Group (RTOG) acute lung injury grading scale, (1) there were occasional cough and dyspnea or there were no obvious respiratory symptoms during exertion, and only X-ray showed that pulmonary inflammatory reaction was grade 1. (2) There were persistent cough and chest tightness, and it was necessary to use narcotic cough medicine to relieve cough, which was grade 2. (3) There was severe cough and chest tightness, and the symptoms cannot be relieved by narcotic cough medicine, and intermittent oxygen inhalation or glucocorticoid treatment was required for grade 3. (4) Difficulty in breathing, insufficiency of ventilation and ventilation, and continuous oxygen inhalation or assisted ventilation were grade 4.

2.4. Data Processing. SPSS 23.0 software was used for data statistics, categorical data were expressed by number (percentage), and chi-square test was used for comparison between two groups. Continuous data were expressed as mean ± standard deviation, and t-test was used for comparison between two groups. The general data of the two groups were analyzed by univariate analysis, and then, the logistic regression analysis was performed to find out the risk factors of acute radiation-induced lung injury induced by radiation therapy for esophageal cancer. Statistical difference was indicated by P < 0.05.

3. Results and Discussion

3.1. The Occurrence of Acute RILI in Patients with Esophageal Cancer after Radiotherapy. The follow-up results showed that after radiotherapy of 206 patients with esophageal cancer in this study, a total of 75 patients developed acute RILI, of which 55 patients had grade 1, 20 had grade 2, and no grade 3 or 4 appeared. The incidence of was 36.41%. 75 patients with acute RILI were included in the observation group, and the remaining 131 patients were included in the control group.

3.2. Univariate Analysis of Acute RILI Induced by Radiotherapy for Esophageal Cancer. Univariate analysis...
showed that there were no significant differences in age, gender, tumor location, tumor stage, smoking history, concurrent chemotherapy, KPS score, V5, V10, V20, and V40 between the two groups (P > 0.05). There were significant differences in the levels of diabetes, total radiotherapy dose, lung disease, physical factors (V30, Dmean), and peripheral blood cytokines (TNF-α, TNF-β, and IL-6) before radiotherapy between the two groups (P < 0.05), as shown in Table 1.

3.3. Multivariate Analysis of Acute RILI Induced by Radiotherapy for Esophageal Cancer. Multivariate logistic regression analysis showed that diabetes, total radiotherapy dose, lung disease, physical factors (V30, Dmean) increased, and cytokines (TNF-α, TNF-β, and IL-6) levels before radiotherapy increased. It was an independent risk factor for acute RILI induced by radiotherapy for esophageal cancer (P < 0.05), as shown in Table 2.

3.4. Discussion. Squamous cell carcinoma and adenocarcinoma are more common in esophageal cancer. According to the location of the tumor center, it can be divided into cervical esophagus cancer, upper thoracic esophageal cancer, middle thoracic esophageal cancer, and lower thoracic esophageal cancer. Middle esophageal cancer is the most common in China, followed by lower esophageal cancer [7, 8]. Symptoms of esophageal cancer are swallowing obstruction and progressive increase. From choking on swallowing and difficulty in eating hard food, it gradually developed into difficulty in eating soft food and drinking water. Its etiology is relatively complex, and it is generally believed to be related to nitrosamines, long-term smoking and drinking, and poor eating habits, and it has a certain genetic susceptibility [9, 10]. In the treatment of early esophageal cancer, surgical resection is the first consideration for resectable esophageal cancer. However, the recurrence and metastasis rate of esophageal cancer after surgery is relatively high. Combined radiotherapy and surgery can increase the surgical resection rate and improve the long-term survival rate. Therefore, radiation therapy is the main treatment for patients with advanced disease [11, 12]. The efficacy of radiation therapy depends on the radiosensitivity, and the degree of response of different tissues and organs and various tumor tissues after exposure to radiation varies [13]. The radiosensitivity of lung tissue is high, and radiotherapy of esophageal cancer is prone to cause acute RILI complications. The clinical manifestations of acute RILI are dry cough with little sputum, dysphagia, chest tightness, and chest pain and in severe cases are dyspnea, low-grade fever, pulmonary congestion, increased alveolar fibrin exudation or formation of hyaline membranes, and finally pulmonary interstitial fibrosis [14, 15]. Acute RILI greatly affects the treatment effect and long-term survival rate of esophageal cancer and reduces the quality of life of patients. Therefore, how to prevent or reduce the concurrent acute RILI during radiotherapy for esophageal cancer has become an increasingly concerned issue for oncology workers.

The results of this study showed that V30, Dmean, and total radiotherapy dose were independent risk factors for inducing acute RILI, which was consistent with the relevant literature reports [16]. It shows that the risk of acute RILI increases significantly after radiotherapy in patients with esophageal cancer with a large area of lung tissue covered by the total dose of radiotherapy, the average dose of both lungs and the large area of lung tissue covered by the radiotherapy field. Therefore, the risk of acute RILI can be reduced by improving the radiotherapy regimen and controlling the dose of radiotherapy.

In terms of cytokines, the results of this study showed that increased levels of TNF-α, TNF-β, and IL-6 in peripheral blood before radiotherapy were independent risk factors for acute RILI. When the levels of TNF-α, TNF-β, and IL-6 were higher, the risk of acute RILI was also increased. TNF-α can initiate an inflammatory response to play an immunoregulatory role. When the level of TNF-α increases, the permeability of vascular endothelial cells can be enhanced, resulting in increased vascular exudation. Second, TNF-α has a chemotactic effect, and a variety of inflammatory cells enter the interstitial space under this effect, thereby producing an inflammatory response. In addition, TNF-α also has the effect of inducing the synthesis and secretion of prostaglandins, which can aggravate the inflammatory response. TNF-β plays an important role in cell growth, differentiation, and immune response. Studies have shown that elevated levels of TNF-beta can increase the risk of radiation-induced lung injury. IL-6 can promote lung fibroblasts to produce a large amount of acute phase proteins such as C-reactive protein, thereby exerting inflammation and immune regulation. The inflammatory state of the body can be reflected by the level of IL-6 in peripheral blood. Therefore, elevated levels of IL-6 may be closely related to radiation-induced lung injury [17].

Pulmonary disease and diabetes were the independent risk factors for radiotherapy-induced acute RILI in patients with esophageal cancer in this study (P < 0.05). Before radiotherapy, patients with pulmonary diseases (such as pneumonia, lung cancer, and bronchial asthma) have increased inflammatory cytokines, and the lung tissue has been damaged by chronic inflammation. At this time, the sensitivity of the lung tissue to radiation is increased, the resistance is low, and the self-repair ability is weakened. Therefore, such patients are more likely to induce radiation-induced lung injury after receiving radiation therapy [18, 19]. In order to prevent pulmonary inflammatory damage in patients, after surgical treatment, patients can be encouraged to improve lung function through abdominal breathing and other training, so as to reduce the risk of lung injury after radiotherapy. Oxygen radicals can kill cells and aggravate tissue damage by disrupting the structure and function of cell membranes. Therefore, after radiotherapy, medical staff can give patients appropriate aerosol treatment, appropriate application of antioxidants such as vitamin C, to reduce the generation of oxygen free radicals and damage to lung tissue cells. Patients with diabetes mellitus have higher blood glucose concentration and higher intravascular osmotic pressure, which may cause damage to the rupture of pulmonary microvessels, resulting in enhanced vascular permeability and increased exudation of inflammatory substances in the radiation field. This can increase the chance of lung damage. Therefore,
| Factors                        | Observation group (n = 75) | Control group (n = 131) | t/χ²   | P      |
|-------------------------------|---------------------------|-------------------------|--------|--------|
| Age, n (%)                    |                           |                         |        |        |
| <60 years                     | 19 (25.33)                | 43 (32.82)              |        |        |
| ≥60 years                     | 56 (74.67)                | 88 (67.18)              |        |        |
| Gender, n (%)                 |                           |                         |        |        |
| Male                          | 41 (54.67)                | 62 (47.33)              |        |        |
| Female                        | 34 (45.33)                | 69 (52.67)              |        |        |
| Tumor location, n (%)         |                           |                         |        |        |
| Upper chest                   | 16 (21.33)                | 21 (16.03)              |        |        |
| Mid chest                      | 39 (52.00)                | 67 (51.15)              |        |        |
| Lower chest                    | 20 (26.67)                | 43 (32.82)              |        |        |
| TNM stage, n (%)              |                           |                         |        |        |
| I                             | 37 (49.33)                | 69 (52.67)              |        |        |
| II-III                        | 26 (34.67)                | 48 (36.64)              |        |        |
| IV                            | 12 (16.00)                | 14 (10.69)              |        |        |
| Smoking history, n (%)        |                           |                         |        |        |
| Yes                           | 47 (62.67)                | 70 (53.44)              |        |        |
| No                            | 28 (37.33)                | 61 (46.56)              |        |        |
| Combined diabetes, n (%)      |                           |                         |        |        |
| Yes                           | 51 (68.00)                | 57 (43.51)              |        |        |
| No                            | 24 (32.00)                | 74 (56.49)              |        |        |
| Concurrent chemotherapy, n (%)|                           |                         |        |        |
| Yes                           | 55 (73.33)                | 89 (67.94)              |        |        |
| No                            | 20 (26.67)                | 42 (32.06)              |        |        |
| Total radiation dose, n (%)   |                           |                         |        |        |
| ≤60 Gy                        | 39 (52.00)                | 91 (69.47)              |        |        |
| >60 Gy                        | 36 (48.00)                | 40 (30.53)              |        |        |
| Combined lung disease, n (%)  |                           |                         |        |        |
| Yes                           | 28 (37.33)                | 23 (17.56)              |        |        |
| No                            | 47 (62.67)                | 108 (82.44)             |        |        |
| KPS score, n (%)              |                           |                         |        |        |
| >80 points                    | 23 (30.67)                | 46 (35.11)              |        |        |
| ≤80 points                    | 52 (69.33)                | 85 (64.89)              |        |        |
| Physical factor               |                           |                         |        |        |
| V5 (Gy)                       | 4421.3 ± 586.4            | 4586.4 ± 591.8          | 1.051* | 0.110  |
| V10 (Gy)                      | 4337.5 ± 536.8            | 4295.8 ± 574.1          | 0.514* | 0.608  |
| V20 (Gy)                      | 2513.7 ± 581.3            | 2431.6 ± 562.5          | 0.996* | 0.321  |
| V30 (Gy)                      | 1124.2 ± 359.7            | 843.1 ± 280.4           | 3.496* | 0.001  |
| V40 (Gy)                      | 364.6 ± 114.4             | 335.3 ± 110.1           | 0.990* | 0.110  |
| Dmean (Gy)                    | 1187.4 ± 343.6            | 913.4 ± 286.5           | 3.412* | 0.001  |
| Cytokines                     |                           |                         |        |        |
| TNF-α (pg/mL)                 | 35.48 ± 11.12             | 21.36 ± 7.49            | 5.958* | <0.001 |
| TNF-β (pg/mL)                 | 57.24 ± 15.92             | 45.67 ± 13.84           | 3.103* | 0.003  |
| IL-6 (pg/mL)                  | 11.59 ± 3.73              | 7.18 ± 2.01             | 5.888* | <0.001 |

Note: #: t-test; ∗: chi-square test; KPS: Karnofsky performance score.
medical staff should pay attention to the changes of blood sugar in patients with esophageal cancer in the process of treatment. In patients with diabetes, glycemic control should be administered to reduce the risk of lung injury following radiotherapy [20]. Since this study is a single-center plan can be adjusted and prepared before radiotherapy, so as to reduce and avoid the induction of acute RILI.

Data Availability
The labeled dataset used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest
The authors declare no competing interests.

References
[1] M. W. Short, K. G. Burgers, and V. T. Fry, “Esophageal cancer,” American Family Physician, vol. 95, no. 1, pp. 22–28, 2017.
[2] F. He, J. Wang, L. Liu et al., “Esophageal cancer: trends in incidence and mortality in China from 2005 to 2015,” Cancer Medicine, vol. 10, no. 5, pp. 1839–1847, 2021.
[3] M. Arnold, I. Soerjomataram, J. Ferlay, and D. Forman, “Global incidence of oesophageal cancer by histological subtype in 2012,” Gut, vol. 64, no. 3, pp. 381–387, 2015.
[4] S. Mönig, M. Chevallay, N. Niclauss et al., “Early esophageal cancer: the significance of surgery, endoscopy, and chemoradiation,” Annals of the New York Academy of Sciences, vol. 1434, no. 1, pp. 115–123, 2018.
[5] C. Puttanawarut, N. Sirirutbunkajorn, S. Khachonkham, P. Pattaranutaporn, and Y. Wongsawat, “Biological dosimetric features for the prediction of radiation pneumonitis in esophageal cancer patients,” Radiation Oncology, vol. 16, no. 1, p. 220, 2021.
[6] M. Stahl, J. Oliveira, and On behalf of the ESMO Guidelines Working Group, “Esophageal cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up,” Annals of Oncology, vol. 20, no. Supplement 4, pp. iv32–iv53, 2009.
[7] M. H. Verstegen, M. Harker, C. van de Water et al., “Metastatic pattern in esophageal and gastric cancer: influenced by site and histology,” World Journal of Gastroenterology, vol. 26, no. 39, pp. 6037–6046, 2020.
[8] B. Li, Y. Zhang, L. Miao et al., “Esophagectomy with three-field versus two-field lymphadenectomy for middle and lower thoracic esophageal cancer: long-term outcomes of a randomized clinical trial,” Journal of Thoracic Oncology, vol. 16, no. 2, pp. 310–317, 2021.
[9] F. L. Huang and S. J. Yu, “Esophageal cancer: risk factors, genetic association, and treatment,” Asian Journal of Surgery, vol. 41, no. 3, pp. 210–215, 2018.
[10] D. J. Uhlenhopp, E. O. Then, T. Sunkara, and V. Gaduputi, “Epidemiology of esophageal cancer: update in global trends, etiology and risk factors,” Clinical Journal of Gastroenterology, vol. 13, no. 6, pp. 1010–1021, 2020.
[11] F. Iriarte, S. Su, R. V. Petrov, C. T. Bakhos, and A. E. Abbas, “Surgical management of early esophageal cancer,” The Surgical Clinics of North America, vol. 101, no. 3, pp. 427–441, 2021.
[12] S. H. Lin, B. P. Hobbs, V. Verma et al., “Randomized phase IIIB trial of proton beam therapy versus intensity-modulated radiation therapy for locally advanced esophageal cancer,” Journal of Clinical Oncology, vol. 38, no. 14, pp. 1569–1579, 2020.
[13] A. Gawish, A. A. Chughtai, and M. J. Eble, “Dosimetric and volumetric effects in clinical target volume and organs at risk during postprostatectomy radiotherapy,” Strahlentherapie und Onkologie, vol. 195, no. 5, pp. 383–392, 2019.
[14] A. N. Hanania, W. Mainwaring, Y. T. Ghebre, N. A. Hanania, and M. Ludwig, “Radiation-induced lung injury: assessment and management,” Chest, vol. 156, no. 1, pp. 150–162, 2019.
[15] Y. Huang, W. Zhang, F. Yu, and F. Gao, “The cellular and molecular mechanism of radiation-induced lung injury,” Medical Science Monitor, vol. 23, pp. 3446–3450, 2017.
[16] I. Madani, K. De Ruyck, H. Goeminne, W. De Neve, H. Thierens, and J. Van Meerbeeck, “Predicting risk of

| Factors                  | B     | SE    | Wald   | P       | OR   | 95% CI       |
|-------------------------|-------|-------|--------|---------|------|--------------|
| Combined diabetes       | 1.848 | 0.910 | 4.124  | <0.001  | 6.345| 2.026–19.877 |
| Combined lung disease   | 1.281 | 0.632 | 4.112  | 0.004   | 3.600| 1.178–11.000 |
| Total radiation dose    | 1.399 | 0.752 | 3.464  | 0.012   | 4.050| 1.306–12.557 |
| V30 (Gy)                | 0.501 | 0.216 | 5.371  | <0.001  | 1.650| 1.272–4.750  |
| Dmean (Gy)              | 0.453 | 0.196 | 5.362  | <0.001  | 1.573| 1.267–4.536  |
| TNF-α (pg/mL)           | 1.564 | 0.931 | 2.822  | 0.003   | 4.778| 2.159–10.782 |
| TNF-β (pg/mL)           | 1.462 | 0.698 | 4.386  | <0.001  | 4.315| 1.134–9.641  |
| IL-6 (pg/mL)            | 1.238 | 0.787 | 2.478  | 0.029   | 3.449| 1.384–9.463  |

4. Conclusion
Diabetes mellitus, pulmonary disease, total radiotherapy dose, elevated physical factors (V30, Dmean), and elevated levels of cytokines (TNF-α, TNF-β, and IL-6) before radiotherapy are the risks of esophageal cancer induced by radiotherapy for acute RILI factor. Before radiotherapy, the possibility of acute RILI can be comprehensively evaluated according to the patient’s condition, and the radiotherapy plan can be adjusted and prepared before radiotherapy, so as to reduce and avoid the induction of acute RILI.
radiation-induced lung injury,” *Journal of Thoracic Oncology*, vol. 2, no. 9, pp. 864–874, 2007.

[17] H. H. Yu, E. Chengchuan Ko, C. L. Chang et al., “Fucoidan inhibits radiation-induced pneumonitis and lung fibrosis by reducing inflammatory cytokine expression in lung tissues,” *Marine Drugs*, vol. 16, no. 10, p. 392, 2018.

[18] F. Cousin, C. Desir, S. Ben Mustapha, C. Mievis, P. Coucke, and R. Hustinx, “Incidence, risk factors, and CT characteristics of radiation recall pneumonitis induced by immune checkpoint inhibitor in lung cancer,” *Radiotherapy and Oncology*, vol. 157, pp. 47–55, 2021.

[19] F. Li, H. Liu, H. Wu, S. Liang, and Y. Xu, “Risk factors for radiation pneumonitis in lung cancer patients with subclinical interstitial lung disease after thoracic radiation therapy,” *Radiation Oncology*, vol. 16, no. 1, p. 70, 2021.

[20] S. Sha, J. Dong, M. Wang, Z. Chen, and P. Gao, “Risk factors for radiation-induced lung injury in patients with advanced non-small cell lung cancer: implication for treatment strategies,” *World Journal of Surgical Oncology*, vol. 19, no. 1, p. 214, 2021.